Company

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials
Dezhan HealthcareSHE: 000813

Dezhan Healthcare Subsidiary Secures FDA IND Clearance for WYY026B Injection in Acute Ischemic Stroke – First‑in‑Class Neuroprotective Agent Advances to U.S. Clinical Trials

Dezhan Healthcare Co., Ltd. (SHE: 000813) announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for WYY026B Injection, a Category 1 chemical…

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

Hengrui Pharma's Fluzoparib Enters EMA Review for Prostate Cancer – First China‑Developed PARP Inhibitor Targets European mCRPC Market

Hengrui Pharma’s Fluzoparib Enters EMA Review for Prostate Cancer – First China‑Developed PARP Inhibitor Targets European mCRPC Market

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial approval / initiationHKG: 2617

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Clinical trial approval / initiationHKG: 2617

TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile

AIHKG: 3696

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

LonzaNona Biosciences

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Show More